Vyome Holdings (HIND) Research & Development (2015 - 2026)
Vyome Holdings (HIND) posted Research & Development of $506723.0 for Q2 2026, down 23.96% on a QoQ basis from $666405.0 in Q1 2026, and up 532.92% year-over-year from $80061.0 in Q2 2025.
Analysis
Vyome Holdings (HIND) Research & Development (2015 - 2026) Analysis & Trends
Vyome Holdings has reported Research & Development for 12 years, with the latest figure at $506723.0 in Q2 2026.
- On a quarterly basis, Research & Development rose 532.92% year-over-year to $506723.0 in Q2 2026; TTM through Jun 2026 was $1.6 million, a 422.22% increase from a year earlier, with the FY2025 full-year figure at $588258.0, up 106.12% from the prior year.
- Research & Development was $506723.0 for Q2 2026 at Vyome Holdings, down from $666405.0 in the prior quarter.
- The five-year high for Research & Development was $6.0 million in Q4 2023, with the low at $39677.0 in Q3 2025.
- Average Research & Development over 5 years is $759429.3, with a median of $524361.5 recorded in 2023.
- The sharpest annual moves came in 2023 and 2024: Research & Development soared 1192.64% in 2023, then sank 98.87% in 2024.
- Over 5 years, Research & Development stood at $462000.0 in 2022, then jumped by 1192.64% to $6.0 million in 2023, then tumbled by 98.87% to $67527.0 in 2024, then soared by 460.15% to $378252.0 in 2025, then surged by 33.96% to $506723.0 in 2026.
- The last three Research & Development figures came in at $506723.0 (Q2 2026), $666405.0 (Q1 2026), and $378252.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | 506,723.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 506,723.00 |
| Mar 31, 2026 | 666,405.00 |
| Dec 31, 2025 | 378,252.00 |
| Sep 30, 2025 | 39,677.00 |
| Jun 30, 2025 | 80,061.00 |
| Mar 31, 2025 | 90,268.00 |
| Dec 31, 2024 | 67,527.00 |
| Sep 30, 2024 | 66,815.00 |
| Jun 30, 2024 | 670,000.00 |
| Mar 31, 2024 | 1.02 Mn |
| Dec 31, 2023 | 5.97 Mn |
| Sep 30, 2023 | 542,000.00 |
| Jun 30, 2023 | 581,000.00 |
| Mar 31, 2023 | 453,000.00 |
| Dec 31, 2022 | 462,000.00 |
| Sep 30, 2022 | 583,000.00 |
| Jun 30, 2022 | 747,000.00 |
| Mar 31, 2022 | 745,000.00 |
| Dec 31, 2021 | 270,000.00 |
| Sep 30, 2021 | 1.43 Mn |